Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameCanbridge-B
Stock Code01228
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities立足中國、專注於罕見病的生物醫藥公司,致力於研究、開發及商業化生物科技療法,產品管線包括13個藥物資產,涵蓋罕見病及罕見腫瘤適應症。
Listing Date2021-12-10
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市朝陽區容創路17號時代凌宇大廈3樓301室
Business Address (Hong Kong)香港尖沙咀廣東道15號海港城港威大廈5座16樓A131室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.canbridgepharma.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 12.18 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 12,180
Par ValueTo be extracted
Offer Period2021-11-30 to 2021-12-03
Global Offering Shares56,251,000 shares
HK Public Offer Shares (Initial)5,626,000 shares (10.0%)
Public Offer Lots (Initial)5,626lots (Pool A2,813lots,Pool B2,813lots)
International Placing Shares (Initial)50,625,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO424,191,920 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share68.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 685,137,180

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 12,180
2 lots 2,000 HK$ 24,360
3 lots 3,000 HK$ 36,540
4 lots 4,000 HK$ 48,720
5 lots 5,000 HK$ 60,900
6 lots 6,000 HK$ 73,080
7 lots 7,000 HK$ 85,260
8 lots 8,000 HK$ 97,440
9 lots 9,000 HK$ 109,620
10 lots 10,000 HK$ 121,800
15 lots 15,000 HK$ 182,700
20 lots 20,000 HK$ 243,600
25 lots 25,000 HK$ 304,500
30 lots 30,000 HK$ 365,400
35 lots 35,000 HK$ 426,300
40 lots 40,000 HK$ 487,200
50 lots 50,000 HK$ 609,000
60 lots 60,000 HK$ 730,800
70 lots 70,000 HK$ 852,600
80 lots 80,000 HK$ 974,400
90 lots 90,000 HK$ 1,096,200
100 lots 100,000 HK$ 1,218,000
150 lots 150,000 HK$ 1,827,000
200 lots 200,000 HK$ 2,436,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
450 lots 450,000 HK$ 5,481,000
1,600 lots 1,600,000 HK$ 19,488,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.27B
Est. Threshold HK$ 9.37B
Analysis Result HK market cap below threshold, need +640%

Valuation & Financials

Market Cap (at Offer Price)HK$ 5,166,657,585
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣846.0百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Revenue 1,44913,002
Cost of sales -494-6,154
Gross profit 9556,848
Other income and gains, net 57012,559
Selling and distribution expenses -28,881-51,008
Administrative expenses -53,619-77,706
Net finance costs -2,275-3,873
Profit before tax -219,075-849,443
Profit for the year -220,475-851,843
Profit attributable to owners -221,875-853,643
Balance Sheet
Item 201920202021-06
Cash and cash equivalents 13,863350,794
Trade and bills receivables 24,58433,557
Inventories 6,57646,703
Total current assets 37,895390,945
Total assets 88,600586,258
Total current liabilities 43,749118,003
Total liabilities 1,079,1962,322,114
Total equity -980,696-1,735,856
Equity attributable to owners -970,701-1,716,861
Interest-bearing borrowings 26,46633,95918,553
Cash Flow Statement
Item 201920202021-06
Net cash from operating activities -127,165-152,638
Net cash from investing activities -42,409-164,473
Net cash from financing activities 96,956678,253
Net increase in cash -72,607373,122
Depreciation of PP&E 1,2771,426953
Depreciation of right-of-use assets 2,3053,4622,573
Amortisation of intangible assets 1312,9513,775
Purchase of PP&E -1,080-2,571-2,773
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 8.9
First Day OpenHK$ 9.8
First Day Change-26.93%
First Day Volume29094800.0
First Day Turnover266971000.0
Use of Proceeds
1、約45.4%或274.2 百萬港元將分配用于為我們的核心產品候選藥物CAN008的現有及日后研發、CMC開發以及生產流程發展提供資金; 2、約24.0%或145.0百萬港元將分配用于為以下我們產品管線中的主要產品及候選產品提供資金; 3、約1.8%或10.9百萬港元將分配用于我們產品管線中其他產品及候選產品的現有及日后研發提供資金; 4、約12.0%或72.5百萬港元,預計用于為CAN201、CAN202及其他基因治療候選藥物的現有及日后研發提供資金; 5、16.8%或101.5百萬港元將分配用于為研發及其他一般業務用途提供資金。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 海通国际证券有限公司 CE AAF806
Joint Bookrunners (5)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 海通国际证券有限公司 CE AAF806 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 中银国际亚洲有限公司 CE AET863
Joint Lead Managers (6)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 海通国际证券有限公司 CE AAF806 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 中银国际亚洲有限公司 CE AET863 富途证券国际(香港)有限公司 CE AZT137

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Belinda A. Termeer 15,578,220 HKD — 2.27% — 6 months 2022-06-10
2 General Atlantic Singapore CP Pte. Ltd. 38,939,460 HKD — 5.68% — 6 months 2022-06-10
3 Hudson Bay Master Fund LTD 62,312,880 HKD — 9.09% — 6 months 2022-06-10
4 Janus Henderson Funds 38,939,460 HKD — 5.68% — 6 months 2022-06-10
5 RA Capital Healthcare Fund, L.P. 233,685,480 HKD — 34.11% — 6 months 2022-06-10
6 江苏瑞华投资控股集团有限公司 38,939,460 HKD — 5.68% — 6 months 2022-06-10
7 药明生物产业基金 38,939,460 HKD — 5.68% — 6 months 2022-06-10

Directors & Management

PositionChinese nameEnglish Name
Chairman薛群—
Company Secretary馬倩、王承鏱—
No director data available.

Major Shareholders

Major Shareholders & Holdings主要股東包括RA Capital Management, L.P.(13.14%)、藥明康德(9.51%)、CTX Pharma(6.14%)、Qiming Corporate GP IV, Ltd.(7.74%)、薛博士(全權信託3.54%、實益2.41%)等。
About this page

This page shows Canbridge-B (01228) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect